PBS Biotech

PBS Biotech

Single-use bioreactors for cell therapy

Research Associate - Bioprocess R&D

Full-TimePosted on 8/3/2026
No salary listed
Mid
Bachelor's, Master's
Camarillo, CA, USA
In Person

Proximity to Ventura County is required, and weekend work may be needed for experiments.

About the job

Requirements
  • A Master's degree in Chemical Engineering, Life Sciences, or Biotechnology, or a Bachelor's degree in those fields with at least 2 years of relevant cell culture laboratory experience.
  • Strong proficiency in Microsoft Excel or other spreadsheet tools.
  • Hands-on experience with pluripotent stem cell, T cell, natural killer cell, or mesenchymal stromal cell process development.
  • Knowledge of cell characterization methodologies such as cell counting and metabolic analysis.
  • Strong organizational skills for developing detailed experimental plans.
  • Strong oral and written communication skills, including generating accurate and timely progress reports.
  • Ability to collaborate with other operators to execute large-scale bioreactor runs.
  • Proximity to Ventura County and a flexible schedule allowing weekend work on experiments as needed.
  • Ability to safely handle chemicals, biological materials, and laboratory equipment while following established safety protocols.
  • Ability to perform prolonged standing, repetitive hand use, occasional lifting of up to 25 pounds, and precise laboratory and manufacturing tasks.
Responsibilities
  • Support laboratory management by maintaining clean and organized laboratory and office spaces, washing and sterilizing glassware, and disposing of biohazard waste according to standard laboratory procedures.
  • Support materials management by purchasing supplies, verifying receipts, restocking materials, and maintaining laboratory inventory logs.
  • Assist with equipment management.
  • Perform daily laboratory activities and assist with experiments as required.
  • Participate in research efforts for various cell culture processes based on client needs.
  • Perform experiments for bioprocess development, optimization, and characterization.
  • Assist in preparing scientific data and composing peer-reviewed publications, white papers, abstracts, and presentations for conferences and trade shows.
  • Support root-cause analysis for unexpected results and develop new approaches or experimental strategies for problem solving.
  • Characterize process and quality attributes of cells during process development independently or with a customer's analytical team or an external service provider.
  • Support internal product improvement efforts by providing biological performance data using PBS products.
  • Collaborate with other departments on cross-functional projects.
Desired Qualifications
  • Ability to shift gears quickly and remain flexible with task assignments based on business needs.
  • Time-management skills and the ability to operate with a sense of urgency to meet deadlines.
  • Positive attitude and team spirit.
  • Excellent collaboration skills.

About the company

PBS Biotech designs, manufactures, and sells single-use bioreactor systems and offers process development and technical support for cell therapy manufacturing. Its core Vertical-Wheel technology provides gentle, homogeneous mixing suitable for shear-sensitive cells like iPSCs and MSCs, enabling scalable suspension or microcarrier culture from research to clinical production. The company operates a B2B model, supplying equipment and disposable components along with customized process development services to academic, biotech, and pharmaceutical customers. With an ISO 9001:2015 certified facility and plans to scale to over $100 million in annual revenue, PBS Biotech aims to expand manufacturing capacity to support commercialization of cell therapies.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$49M

Headquarters

Camarillo, California

Founded

2006

Get referred to PBS Biotech

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • PBS won Life Sciences Review's 2026 Cell Therapy Products Development of the Year.
  • September 2026 website promos and credits push adoption of PBS-Mini and repeat purchases.
  • denovoMATRIX collaboration expands iPSC manufacturing workflows beyond core bioreactor sales.

What critics are saying

  • Thermo Fisher, Cytiva, Sartorius, and Merck dominate large-scale bioreactor procurement.
  • PBS tops out at 80 liters, blocking many commercial manufacturing programs.
  • If cell-therapy funding stays weak into 2027, equipment orders and service revenue contract.

What makes PBS Biotech unique

  • Vertical-Wheel technology gives PBS Biotech low-shear mixing for fragile cell therapies.
  • Martin Simonetti became CEO in October 2025, sharpening commercialization and capital discipline.
  • Patented bioreactors scale from PBS-MiniPRO to PBS-80, spanning research through manufacturing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 0%

2 year growth

↑ 5%
Business Wire
Sep 16th, 2026
PBS Biotech Raises $10M to Provide Scale-Up Manufacturing Solutions for Cell Therapies

Single-use bioreactor manufacturer, PBS Biotech, recently closed a private $10M funding round with BroadOak Capital Partners. The financing will enable the c...

PR Newswire
Jul 21st, 2026
PBS Biotech wins 2026 cell Products Development of the Year award.

PBS Biotech wins 2026 cell Products Development of the Year award. Jul 21, 2026, 07:00 ET Recognition Highlights Company's Leadership in Advancing Linearly Scalable, Advanced Cell Therapy Manufacturing CAMARILLO, Calif., July 21, 2026 /PRNewswire/ - PBS Biotech, a leading developer of innovative single-use bioreactor technologies for cell therapy manufacturing, today announced it has been named Cell Therapy Products Development of the Year 2026 by Life Sciences Review. The company was also recognized among the publication's Top Companies in Cell and Gene Therapy, underscoring PBS Biotech's growing impact on the future of advanced therapeutic manufacturing. The recognition reflects PBS Biotech's continued commitment to helping cell therapy developers overcome one of the industry's greatest challenges: reliably scaling manufacturing while preserving cell quality and function. Through its patented Vertical-Wheel(R) bioreactor technology, PBS Biotech enables gentle, low-shear cell culture that supports the expansion and differentiation of a broad range of sensitive cell types, from early process development through commercial manufacturing. "As cell therapies continue to transform medicine, manufacturers need technologies that eliminate the traditional tradeoff between scalability and cell quality," said Martin Simonetti, Chief Executive Officer of PBS Biotech. "We're honored that Life Sciences Review has recognized our team's dedication to advancing manufacturing solutions that help bring life-changing therapies to patients faster." Unlike conventional stirred-tank bioreactors, PBS Biotech's Vertical-Wheel platform was specifically engineered to create homogeneous mixing with exceptionally low shear forces, providing an environment well suited for sensitive cell types including induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), T cells, NK cells, CAR-T, CAR-NK, and pancreatic islet cells. The technology offers linear scalability from research through manufacturing, enabling customers to simplify process development and accelerate technology transfer. In its feature, Life Sciences Review highlighted PBS Biotech's customer-centric approach, commitment to innovation, and expanding collaborations across the cell and gene therapy ecosystem. The publication also recognized the company's role in helping developers address critical manufacturing bottlenecks as more cell therapies advance toward commercialization. "This recognition belongs to our employees, customers, collaborators, and partners who continue pushing the boundaries of regenerative medicine," Simonetti added. "Together, we're building the manufacturing foundation that will enable the next generation of cell therapies to reach more patients around the world." As demand for scalable, robust manufacturing platforms continues to grow, PBS Biotech remains focused on expanding its technology portfolio, supporting customer success, and advancing manufacturing solutions that accelerate the commercialization of transformative cell therapies. About PBS Biotech PBS Biotech is a biotechnology company dedicated to advancing the manufacture of next-generation cell therapies through innovative bioreactor technologies. Its patented Vertical-Wheel(R) bioreactor platform delivers gentle, low-shear mixing with scalable performance to support process development, clinical manufacturing, and commercial production. PBS Biotech partners with leading biotechnology companies, CDMOs, and academic institutions worldwide to accelerate the development and commercialization of life-changing cell therapies. About Forward-Looking Statements This press release contains forward-looking statements regarding PBS Biotech's future plans, expectations, and business outlook, including statements related to the development, adoption, and commercialization of cell therapy manufacturing technologies. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. PBS Biotech undertakes no obligation to update any forward-looking statements as a result of new information, future events, or otherwise. Media Contact SOURCE PBS Biotech Inc.

FinSMEs
Jan 6th, 2025
PBS Biotech Raises $17M in Growth Funding

PBS Biotech raises $17M in Growth funding.

Pulse 2.0
Jan 6th, 2025
PBS Biotech Raises $17M for Growth

PBS Biotech raised $17 million in growth capital from Avego Management and BroadOak Capital Partners to enhance product innovation, process development, and quality systems. The company is expanding its ISO 9001:2015 manufacturing capacity to support over $100 million in annual revenue by mid-2025. PBS appointed Terrell Mathews as Chief Commercial Officer and Erik Wiberg as Chief Financial Officer to drive strategic growth and strengthen its market position in the cell therapy industry.

PR Newswire
Jan 6th, 2025
PBS Biotech Expands Leadership Team and Secures $17 Million in Growth Capital to Accelerate Delivery of Next Generation Cell and Regenerative Therapies

/PRNewswire/ -- PBS Biotech ("PBS"), a provider of innovative single-use bioreactor systems and bioprocess development services, has secured $17 million in...

INACTIVE